ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Contact
✕

Blog

  • Home
  • Blog

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results
  • Uncategorized

Archives

  • January 2025
  • September 2024
  • July 2024
  • March 2024
  • January 2024
  • October 2023
  • July 2023
  • March 2023
  • January 2023
  • September 2022
  • June 2022
  • March 2022
  • December 2021
  • September 2021
  • June 2021
  • March 2021
  • October 2020
  • June 2020
  • February 2020
  • October 2019

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts

Tags

Acute lymphoblastic leukemia Adolescents and young adults Advocacy Bladder cancer Breast cancer Caregiving ComboMATCH Communication De-escalation Head and neck cancer Health equity HER2+ breast cancer Immune system therapy Immunotherapy In memory Kidney cancer Leukemia Lung cancer Lymphoma Mammography Mantle cell lymphoma Melanoma Multiple myeloma Myeloma NCI-MATCH Nose and sinus cancer Pancreatic cancer Pancreatic cysts Patient care Personalized medicine Personalized screening Personalized treatment Precision medicine Prevention Prostate cancer Renal cell carcinoma Research results Screening Side effects Squamous cell carcinoma Surveillance Survivorship Symptom management Targeted therapy Throat cancer
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2025 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc